Fibrodyne Limited 13910138 true 2024-03-01 2025-02-28 2025-02-28 The principal activity of the company is providing professional, scientific and technical services. Digita Accounts Production Advanced 6.30.9574.0 true Prof F M Watt 13910138 2024-03-01 2025-02-28 13910138 2025-02-28 13910138 bus:OrdinaryShareClass1 2025-02-28 13910138 core:RetainedEarningsAccumulatedLosses 2025-02-28 13910138 core:ShareCapital 2025-02-28 13910138 core:CurrentFinancialInstruments core:WithinOneYear 2025-02-28 13910138 bus:FRS102 2024-03-01 2025-02-28 13910138 bus:AuditExempt-NoAccountantsReport 2024-03-01 2025-02-28 13910138 bus:FullAccounts 2024-03-01 2025-02-28 13910138 bus:RegisteredOffice 2024-03-01 2025-02-28 13910138 bus:Director1 2024-03-01 2025-02-28 13910138 bus:EntityHasNeverTraded 2024-03-01 2025-02-28 13910138 bus:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 13910138 bus:Agent1 2024-03-01 2025-02-28 13910138 countries:EnglandWales 2024-03-01 2025-02-28 13910138 2023-03-01 2024-02-29 13910138 2024-02-29 13910138 bus:OrdinaryShareClass1 2024-02-29 13910138 core:RetainedEarningsAccumulatedLosses 2024-02-29 13910138 core:ShareCapital 2024-02-29 13910138 core:CurrentFinancialInstruments core:WithinOneYear 2024-02-29 iso4217:GBP xbrli:shares xbrli:pure

Registration number: 13910138

Fibrodyne Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 28 February 2025

 

Fibrodyne Limited

Contents

Company Information

1

Income Statement

2

Statement of Financial Position

3

Notes to the Unaudited Financial Statements

4 to 5

 

Fibrodyne Limited

Company Information

Director

Prof F M Watt

Registered office

163 Herne Hill
London
SE24 9LR

Accountants

Innovi Advisors Ltd
Chartered Certified Accountants163 Herne Hill
London
SE24 9LR

 

Fibrodyne Limited

Income Statement for the Year Ended 28 February 2025

The company has not traded during the year. During this year, the company received no income and incurred no expenditure and therefore made neither profit nor loss.

 

Fibrodyne Limited

(Registration number: 13910138)
Statement of Financial Position as at 28 February 2025

Note

2025
£

2024
£

Current assets

 

Cash at bank and in hand

 

1,000

1,000

Creditors: Amounts falling due within one year

4

(2,050)

(1,690)

Net liabilities

 

(1,050)

(690)

Capital and reserves

 

Called up share capital

5

30

30

Retained earnings

(1,080)

(720)

Shareholders' deficit

 

(1,050)

(690)

For the financial year ending 28 February 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

Approved and authorised by the director on 4 March 2025
 

.........................................
Prof F M Watt
Director

 

Fibrodyne Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
163 Herne Hill
London
SE24 9LR
England

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The presentation currency of the financial statements is Pound Sterling (£) rounded to the nearest Pound.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Cash and cash equivalents

2025
£

2024
£

Cash at bank

1,000

1,000

 

Fibrodyne Limited

Notes to the Unaudited Financial Statements for the Year Ended 28 February 2025 (continued)

4

Creditors

Note

2025
£

2024
£

Due within one year

 

Amounts due to related parties

1,690

1,330

Accruals

 

360

360

 

2,050

1,690

5

Share capital

Allotted, called up and fully paid shares

 

2025

2024

 

No.

£

No.

£

Ordinary shares of £0.001 each

30,000

30.00

30,000

30.00

         

6

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 0 (2024 - 0).